Loading
A phase 2 trial of Zanidatamab in oesophageal cancer and colorectal cancer, run by Jazz Pharmaceuticals, now recruiting.
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors is a phase 2 interventional study registered as NCT06695845 by Jazz Pharmaceuticals, with 200 participants planned, started 2025-01-14 and due to reach its primary completion in 2026-12-31. Interventions recorded: Zanidatamab. Conditions listed: Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Jazz Pharmaceuticals, Zanidatamab, HER2-amplified colorectal cancer.
Shares Jazz Pharmaceuticals, Zanidatamab, Bispecific antibodies.
Shares Jazz Pharmaceuticals, Zanidatamab, Bispecific antibodies, Oesophageal cancer.
Shares HER2-mutant non-small-cell lung cancer, Small-cell lung cancer, Non-small-cell lung cancer.
Shares HER2-mutant non-small-cell lung cancer, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Jazz Pharmaceuticals, Zanidatamab, Bispecific antibodies.
Shares HER2-mutant non-small-cell lung cancer, Endometrial cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/